Several agonistic antibodies are currently under investigation in clinical trials. For instance, CD40 agonistic antibodies are being explored for their potential to stimulate anti-tumor immune responses. Similarly, agonistic antibodies targeting OX40 and 4-1BB receptors are being tested for their efficacy in enhancing T-cell activation and proliferation in cancer immunotherapy. These examples highlight the potential of agonistic antibodies to modulate immune responses effectively.
